IACH Focus on Leukemia 2020 | New treatments for AML
Thomas Prebet, MD, Yale School of Medicine, New Haven, CT, discusses the developments in novel treatments for acute myeloid leukemia (AML). The landscape has changed over the last few years with the addition of new agents that can be used alongside conventional chemotherapy. This includes targeted therapies that have been recently defined by molecular aberrations, such as IDH and FLT3 mutations. There have also been new therapies that are not specific, which include monoclonal antibodies and BCL-2 inhibitors. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
Disclosures
Thomas Prebet, MD, has done consultancy work and received research support from Otsuka, Genentech, Abbvie and Jazz Pharma.
